Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1877758 | Applied Radiation and Isotopes | 2011 | 4 Pages |
The purpose of this analysis was to assess the potential of BNCT, with l-boronophenylalanine (l-BPA), as first line radiotherapy for glioblastoma multiforme (GBM). The survival of patients with newly diagnosed GBM from a phase II BNCT study was compared with those from the two arms of a phase III study with conventional radiotherapy (RT) vs. RT plus concomitant and adjuvant medication with temozolomide (TMZ). A small subgroup, for which the methylation status of the O6-methylguanine–DNA methyltransferase (MGMT) DNA-repair gene was known, was also considered. The results indicated that the use of BNCT with BPA should be explored in a stratified randomized phase II trial in which patients with the unmethylated MGMT DNA-repair gene are offered BNCT vs. RT plus TMZ.